45 research outputs found

    First total synthesis of (4R,5R,11S) and (4R,5R,11R)-isocladospolide B

    Get PDF
    The two enantiomers of natural products (4<em>S</em>, 5<em>S</em>, 11<em>R</em>)-and (4<em>S</em>, 5<em>S</em>, 11<em>S</em>)-<em>iso</em>-cladospolide B have been synthesized and their structures unambiguously confirmed by X-ray crystallographic analysis. Key steps of the synthesis include the use of tri-O-acetyl-D-glucal as precursor for a chiral furan diol which, after side chain transformation, underwent singlet oxygen oxidation to afford the target butenolide

    Spanish citizens’ opinions on future trends in cardiology as expressed in digital ecosystems

    Get PDF
    [Abstract] Patient-centred medicine is a healthcare approach that focuses on patients’ wants, needs and preferences. An obstacle to implement patient-centred medicine is the difficulty of obtaining data that is relevant and representative of the whole society. In 2019, the Spanish Society of Cardiology highlighted eight trends that would exert a determining influence on the future of cardiology: “demographics”, “economic environment”, “political environment”, “citizens’ expectations”, “incorporation of women”, “technological innovation”, “health levels and cardiovascular risk factors” and “healthcare organisation and management”. In order to assess these trends from a pacient-centred approach, the aim of this study is to evaluate the opinions of the individuals who are part of Spanish society, regarding the eight trends identified by the Spanish Society of Cardiology, using natural language processing tools to analyse the communications expressed by citizens in digital ecosystems and official channels of communication. We analysed communications published between 2007 and 2019. Natural language processing identified 17 areas of opinion that support the eight trends. We evaluated the impact of each area of opinion based on the standard metrics of online reputation: presence, emotion and reach. Thus, 257,456 communications were analysed. The most relevant trend was “healthcare organisation and management” (54% of the total impact), followed by “health levels and cardiovascular risk factors” and “demographics” (14% and 10%, respectively). The least relevant trend was “citizens’ expectations” (1%). Within the areas of opinion identified, the one with greatest impact was “the cardiologist” (16% of the total impact). In conclusion, the results of this research show that natural language processing tools are a useful tool for patient-centred medicine. The high impact associated with the cardiologist’s role, together with the low impact observed for “citizen’s expectations” show that Spanish citizens identify the cardiologist as the leading figure regarding their cardiovascular health

    The UVB1 Vitamin D Analogue Inhibits Colorectal Carcinoma Progression

    Get PDF
    Vitamin D has been shown to display a wide variety of antitumour effects, but their therapeutic use is limited by its severe side effects. We have designed and synthesized a Gemini vitamin D analogue of calcitriol (UVB1) which has shown to display antineoplastic effects on different cancer cell lines without causing hypercalcemia. The aim of this work has been to investigate, by employing in silico, in vitro, and in vivo assays, whether UVB1 inhibits human colorectal carcinoma progression. We demonstrated that UVB1 induces apoptotic cell death and retards cellular migration and invasion of HCT116 colorectal carcinoma cells. Moreover, the analogue reduced the tumour volume in vivo, and modulated the expression of Bax, E-cadherin and nuclear ÎČ-catenin in tumour animal tissues without producing toxic effects. In silico analysis showed that UVB1 exhibits greater affinity for the ligand binding domain of vitamin D receptor than calcitriol, and that several characteristics in the three-dimensional conformation of VDR may influence the biological effects. These results demonstrate that the Gemini vitamin D analogue affects the growth of the colorectal cancer and suggest that UVB1 is a potential chemotherapeutic agent for treatment of this disease.Fil: Ferronato, MarĂ­a Julia. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Alonso, Eliana Noelia. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Gandini, Norberto Ariel. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Fermento, MarĂ­a Eugenia. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Villegas, MarĂ­a Emilia. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Quevedo, Mario Alfredo. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - CĂłrdoba. Unidad de InvestigaciĂłn y Desarrollo en TecnologĂ­a FarmacĂ©utica. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂ­micas. Unidad de InvestigaciĂłn y Desarrollo en TecnologĂ­a FarmacĂ©utica; ArgentinaFil: Arevalo, Julian. Hospital Municipal General de Agudos Doctor JosĂ© Penna; ArgentinaFil: LĂłpez Romero, Alejandro. Laboratorios IACA. Departamento de HematologĂ­a; ArgentinaFil: Rivadulla, Marcos Lois. Universidad de Vigo. Facultad de Ciencias; EspañaFil: GĂłmez, Generosa. Universidad de Vigo. Facultad de Ciencias; EspañaFil: Fall, Yagamare. Universidad de Vigo. Facultad de Ciencias; EspañaFil: Facchinetti, Maria Marta. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; ArgentinaFil: Curino, Alejandro Carlos. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Centro CientĂ­fico TecnolĂłgico Conicet - BahĂ­a Blanca. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca. Universidad Nacional del Sur. Instituto de Investigaciones BioquĂ­micas de BahĂ­a Blanca; Argentin

    Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study

    Get PDF
    [Abstract] BACKGROUND: New biomarkers are necessary to improve detection of the risk of infection in heart transplantation. We performed a multicenter study to evaluate humoral immunity profiles that could better enable us to identify heart recipients at risk of severe infections. METHODS: We prospectively analyzed 170 adult heart recipients at 8 centers in Spain. Study points were before transplantation and 7 and 30 days after transplantation. Immune parameters included IgG, IgM, IgA and complement factors C3 and C4, and titers of specific antibody to pneumococcal polysaccharide antigens (anti-PPS) and to cytomegalovirus (CMV). To evaluate potential immunologic mechanisms leading to IgG hypogammaglobulinemia, before heart transplantation we assessed serum B-cell activating factor (BAFF) levels using enzyme-linked immunoassay. The clinical follow-up period lasted 6 months. Clinical outcome was need for intravenous anti-microbials for therapy of infection. RESULTS: During follow-up, 53 patients (31.2%) developed at least 1 severe infection. We confirmed that IgG hypogammaglobulinemia at Day 7 (defined as IgG <600 mg/dl) is a risk factor for infection in general, bacterial infections in particular, and CMV disease. At Day 7 after transplantation, the combination of IgG <600 mg/dl + C3 <80 mg/dl was more strongly associated with the outcome (adjusted odds ratio 7.40; 95% confidence interval 1.48 to 37.03; p = 0.014). We found that quantification of anti-CMV antibody titers and lower anti-PPS antibody concentrations were independent predictors of CMV disease and bacterial infections, respectively. Higher pre-transplant BAFF levels were a risk factor of acute cellular rejection. CONCLUSION: Early immunologic monitoring of humoral immunity profiles proved useful for the identification of heart recipients who are at risk of severe infection.Instituto de Salud Carlos III; FIS081430Instituto de Salud Carlos III; FIS1101323Instituto de Salud Carlos III; FIS150147

    Registro Español de Trasplante Cardiaco: XXXI Informe Oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología

    Get PDF
    [Abstract] Introduction and objectives. The present report describes the clinical characteristics and outcomes of heart transplants in Spain and updates the data to 2019. Methods. We describe the clinical characteristics and outcomes of heart transplants performed in Spain in 2019, as well as trends in this procedure from 2010 to 2018. Results. In 2019, 300 transplants were performed (8794 since 1984; 2745 between 2010 and 2019). Compared with previous years, the most notable findings were the decreasing rate of urgent transplants (38%), and the consolidation of the type of circulatory support prior to transplant, with an almost complete disappearance of counterpulsation balloon (0.7%), stabilization in the use of extracorporeal membrane oxygenation (9.6%), and an increase in the use of ventricular assist devices (29.0%). Survival from 2016 to 2018 was similar to that from 2013 to 2015 (P=.34). Survival in both these periods was better than that from 2010 to 2012 (P=.002 and P=.01, respectively). Conclusions. Heart transplant activity has remained stable during the last few years, as have outcomes (in terms of survival). There has been a trend to a lower rate of urgent transplants and to a higher use of ventricular assist devices prior to transplant.[Resumen] IntroducciĂłn y objetivos. Se presentan las caracterĂ­sticas clĂ­nicas y los resultados de los trasplantes cardiacos realizados en España con la actualizaciĂłn correspondiente a 2019. MĂ©todos. Se describen las caracterĂ­sticas clĂ­nicas y los resultados de los trasplantes cardiacos realizados en 2019, asĂ­ como las tendencias de estos en el periodo 2010-2018. Resultados. En 2019 se realizaron 300 trasplantes (8.794 desde 1984; 2.745 entre 2010 y 2019). Respecto a años previos, los cambios mĂĄs llamativos son el descenso hasta el 38% de los trasplantes realizados en cĂłdigo urgente, y la consolidaciĂłn en el cambio de asistencia circulatoria pretrasplante, con la prĂĄctica desapariciĂłn del balĂłn de contrapulsaciĂłn (0,7%), la estabilizaciĂłn del uso del oxigenador extracorpĂłreo de membrana (9,6%) y el aumento de los dispositivos de asistencia ventricular (29%). La supervivencia en el trienio 2016-2018 es similar a la del trienio 2013-2015 (p=0,34), y ambas mejores que la del trienio 2010-2012 (p=0,002 y p=0,01 respectivamente). Conclusiones. Se mantienen estables tanto la actividad del trasplante cardiaco en España como los resultados en supervivencia en los Ășltimos 2 trienios. Hay una tendencia a realizar menos trasplantes urgentes, la mayorĂ­a con dispositivos de asistencia ventricular

    In-hospital postoperative infection after heart transplantation: risk factors and development of a novel predictive score

    Get PDF
    [Abstract] Introduction: Infection is one of the most significant complications following heart transplantation (HT). The aim of this study was to identify specific risk factors for early postoperative infections in HT recipients, and to develop a multivariable predictive model to identify HT recipients at high risk. Methods: A single-center, observational, and retrospective study was conducted. The dependent variable was in-hospital postoperative infection. We examined demographic and epidemiological data from donors and recipients, surgical features, and adverse postoperative events as independent variables. Backwards, stepwise multivariable logistic regression with a P-value < 0.05 was used to identify clinical factors independently associated with the risk of in-hospital postoperative infections following HT. Results: Six hundred seventy-seven patients were included in this study. During the in-hospital postoperative period, 348 episodes of infection were diagnosed in 239 (35.9%) patients. Seven variables were identified as independent clinical predictors of early postoperative infection after HT: history of diabetes mellitus, previous sternotomy, preoperative mechanical ventilation, primary graft failure, major surgical bleeding, use of mycophenolate mofetil, and use of itraconazole. Based on the results of multivariable models, we constructed a 7-variable (8-point) score to predict the risk of in-hospital postoperative infection in HT recipients, which showed a reasonable ability to predict the risk of in-hospital postoperative infection in this population. Prospective external validation of this new score is warranted to confirm its clinical applicability. Conclusions: In-hospital postoperative infection is a common complication after HT, affecting 35% of patients who underwent this procedure at our institution. Diabetes mellitus, previous sternotomy, preoperative mechanical ventilation, primary graft failure, major surgical bleeding, use of mycophenolate mofetil, and itraconazole were all independent clinical predictors of early postoperative infection after HT

    In-Hospital Post-Operative Infection after Heart Transplantation: Epidemiology, Clinical Management, and Outcome

    Get PDF
    Observational study[Abstract] Background: Infection is a major cause of morbidity and mortality after heart transplantation (HT). Little information about its importance in the immediate post-operative period is available. The aim of this study was to analyze the characteristics, incidence, and outcomes of in-hospital post-operative infections after HT. Methods: We conducted an observational, single-center study based on 677 adults who underwent HT from 1991 to 2015 and who survived the surgical intervention. In-hospital post-operative infections were identified retrospectively according to the medical finding in the clinical records. Results: Over a mean hospital stay of 24.5 days, 239 patients (35.3%) developed 348 episodes of infection (2 episodes per 100 patient-days). The most common sources of infection were those related to invasive procedures (respiratory infections, 115 [33%]; urinary tract infections, 47 [13.5%]; bacteremia, 42 [12.1%]; surgical site infections, 25 [7.2%]), in addition to abdominal focus (33, 9.5%). Enterobacteriaceae (76, 21.8%) and gram-positive cocci (58, 16.7%) were the predominant germs, although opportunistic infections were not infrequent (69, 19.8%). Ninety-five septic episodes were detected with a mean Sequential Organ Failure Assessment Score of 9.5 ± 5.3 points, with hemodynamic failure being the most severe organ dysfunction and renal dysfunction the most frequent one. Management included broad-spectrum antibiotics in 48.8% of episodes and surgical management in 13.8%. The overall antimicrobial success rate was 96.3%. Higher in-hospital mortality was observed among infected patients (15.1% vs. 10.3%), but this difference was not statistically significant (p = 0.067). The one-year survival and events were not different between patients suffering from a post-operative infection and those who did not. Conclusions: In-hospital infections were frequent in the post-operative period after HT and were associated with a poor short-term outcome. Patients who survived sepsis had a similar one-year morbidity and mortality compared with patients who did not develop an infection

    Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure

    Get PDF
    [Abstract] Epicardial adipose tissue has been proposed to participate in the pathogenesis of heart failure. The aim of our study was to assess the expression of thermogenic genes (Uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), and PR-domain-missing 16 (PRDM16) in epicardial adipose tissue in patients with heart failure, stablishing the difference according to left ventricular ejection fraction (reduced or preserved). Among the 75 patients in our study, 42.7% (n=32) had reduced left ventricular ejection fraction. UCP1, PGC1α and PRDM16 mRNA in EAT were significantly lower in patients with reduced left ventricular ejection fraction. Multiple regression analysis showed that age, male gender, body max index, presence of obesity, type-2-diabetes mellitus, hypertension and coronary artery disease and left ventricular ejection fraction were associated with the expression levels of UCP1, PGC1α and PRDM16 mRNA. Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and type-2-diabetes mellitus (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors. The adequate expression of thermogenic genes has been shown as possible protective factors against heart failure with reduced ejection fraction, suggesting that a loss of functional epicardial adipose tissue brown-like features would participate in a deleterious manner on heart metabolism. Thermogenic genes could represent a future novel therapeutic target in heart failure.Ministerio de Salud, Servicios Sociales e Igualdad; PI13/02542Ministerio de Salud, Servicios Sociales e Igualdad; PI11/01661Red de Investigación Cardiovascular (España), RD12/0042/003

    Prognostic value of discharge heart rate in acute heart failure patients: more relevant in atrial fibrillation?

    Get PDF
    [Abstract] Aims. The prognostic impact of heart rate (HR) in acute heart failure (AHF) patients is not well known especially in atrial fibrillation (AF) patients. The aim of the study was to evaluate the impact of admission HR, discharge HR, HR difference (admission-discharge) in AHF patients with sinus rhythm (SR) or AF on long- term outcomes. Methods. We included 1398 patients consecutively admitted with AHF between October 2013 and December 2014 from a national multicentre, prospective registry. Logistic regression models were used to estimate the association between admission HR, discharge HR and HR difference and one- year all-cause mortality and HF readmission. Results. The mean age of the study population was 72 ± 12 years. Of these, 594 (42.4%) were female, 655 (77.8%) were hypertensive and 655 (46.8%) had diabetes. Among all included patients, 745 (53.2%) had sinus rhythm and 653 (46.7%) had atrial fibrillation. Only discharge HR was associated with one year all-cause mortality (Relative risk (RR) = 1.182, confidence interval (CI) 95% 1.024–1.366, p = 0.022) in SR. In AF patients discharge HR was associated with one year all cause mortality (RR = 1.276, CI 95% 1.115–1.459, p ≀ 0.001). We did not observe a prognostic effect of admission HR or HRD on long-term outcomes in both groups. This relationship is not dependent on left ventricular ejection fraction. Conclusions. In AHF patients lower discharge HR, neither the admission nor the difference, is associated with better long-term outcomes especially in AF patients

    Conversion from immediate-release tacrolimus to prolonged-release tacrolimus in stable heart transplant patients: a retrospective study

    Get PDF
    [Abstract] Background Lifelong adherence with post-transplant immunosuppression is challenging, with nonadherence associated with greater acute rejection (AR) risk. Methods This retrospective study evaluated conversion from immediate-release tacrolimus (IRT) to prolonged-release tacrolimus (PRT), between January 2008 and December 2012 in stable adult heart transplant recipients. Cumulative incidence rate (IR) of AR and infection pre- and postconversion, safety, tacrolimus dose and trough levels, concomitant immunosuppression, and PRT discontinuation were analyzed (intention-to-treat population). Results Overall, 467 patients (mean age, 59.3 [SD, 13.3] years) converted to PRT at 5.1 (SD, 4.9) years post transplant and were followed for 3.4 (SD, 1.5) years. During the 6 months post conversion, 5 patients (1.1%; 95% CI, 0.35%–2.48%) had an AR episode and IR was 2.2/100 patient-years (95% CI, 0.91–5.26). Incidence of rejection preconversion varied by time from transplant to conversion. Infection IR was similar post- and preconversion (9.2/100 patient-years [95% CI, 7.4–11.3] vs 10.6/100 patient-years [95% CI, 8.8–12.3], respectively; P = .20). Safety variables remained similar post conversion. The IR of mortality/graft loss was 2.3/100 patient-years (95% CI, 1.7–3.1). Conclusions Conversion from IRT to PRT in heart transplant recipients in Spain was associated with no new safety concerns and appropriate immunosuppressive effectiveness
    corecore